ArticlePloS one2008
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 90 citations in OpenAlex.
- Establishment and characterization of a new immortalized human adenomyosis epithelial-like cell line, tAEC21†.Biology of reproduction · 2026Article
- The present and future of the Cancer Dependency Map.Nature reviews. Cancer · 2025Review
- Characterisation of cell lines derived from prostate cancer patients with localised disease.Prostate cancer and prostatic diseases · 2023Article
- Experimental in vitro, ex vivo and in vivo models in prostate cancer research.Nature reviews. Urology · 2023Review
- Proteasome-Mediated Regulation of GATA2 Expression and Androgen Receptor Transcription in Benign Prostate Epithelial Cells.Biomedicines · 2022Article
- LMNB1, a potential marker for early prostate cancer progression.American journal of cancer research · 2022Article
- Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomerase.Prostate cancer and prostatic diseases · 2021Article
- Integrin α11 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence.Cancer science · 2020Article
- Calcium Carbonate Nanoparticles Can Activate the Epithelial⁻Mesenchymal Transition in an Experimental Gastric Cancer Model.Biomedicines · 2019Article
- Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts.Frontiers in oncology · 2018Article
- Young Bone Marrow Sca-1 Cells Rejuvenate the Aged Heart by Promoting Epithelial-to-Mesenchymal Transition.Theranostics · 2018Article
- An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.PloS one · 2017Article
- Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.BMC cancer · 2016Article
- Stromal Integrin α11β1 Affects RM11 Prostate and 4T1 Breast Xenograft Tumors Differently.PloS one · 2016Article
- ΔNp63α Transcriptionally Regulates the Expression of CTEN That Is Associated with Prostate Cell Adhesion.PloS one · 2016Article
- Membrane-associated collagens with interrupted triple-helices (MACITs): evolution from a bilaterian common ancestor and functional conservation in C. elegans.BMC evolutionary biology · 2015Article
- The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.Cancer metastasis reviews · 2014Review
- Response to "Comment on 'A method to measure cellular adhesion utilizing a polymer micro-cantilever'" [Appl. Phys. Lett.Applied physics letters · 2014Article
- A method to measure cellular adhesion utilizing a polymer micro-cantilever.Applied physics letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpithelial to mesenchymal transition (EMT) has been connected with cancer progression in vivo and the generation of more aggressive cancer cell lines in vitro. EMT has been induced in prostate cancer cell lines, but has previously not been shown in primary prostate cells. The role of EMT in malignant transformation has not been clarified. METHODOLOGY/PRINCIPAL
findingsIn a transformation experiment when selecting for cells with loss of contact inhibition, the immortalized prostate primary epithelial cell line, EP156T, was observed to undergo EMT accompanied by loss of contact inhibition after about 12 weeks in continuous culture. The changed new cells were named EPT1. EMT of EPT1 was characterized by striking morphological changes and increased invasion and migration compared with the original EP156T cells. Gene expression profiling showed extensively decreased epithelial markers and increased mesenchymal markers in EPT1 cells, as well as pronounced switches of gene expression modules involved in cell adhesion and attachment. Transformation assays showed that EPT1 cells were sensitive to serum or growth factor withdrawal. Most importantly, EPT1 cells were not able to grow in an anchorage-independent way in soft agar, which is considered a critical feature of malignant transformation. CONCLUSIONS/SIGNIFICANCE: This work for the first time established an EMT model from primary prostate cells. The results show that EMT can be activated as a coordinated gene expression program in association with early steps of transformation. The model allows a clearer identification of the molecular mechanisms of EMT and its potential role in malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.